Program
gedatolisib
Also written as “PF-05212384”, “Gedatolisib” and “Arm A: Gedatolisib + Palbociclib + Fulvestrant”.
Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Prostatic Neoplasms, Castration-Resistant · Endometrial Neoplasms · Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 50 open or running | phase 2since Aug 17, 2011 | Jul 14, 2009 | none ahead |
| Celcuity | 43 open or running | phase 3since Aug 12, 2022 | Feb 10, 2016 | Jan 2028phase 2 · NCT06190899 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2009First study: phase 1 study in NeoplasmsNew to PfizerPfizer · NCT00940498 · 78 enrolled · United States, Spain, United Kingdom
- Aug 17, 2011Phase 2 study in Endometrial NeoplasmsPfizer · NCT01420081 · 67 enrolled · United States, Australia, Canada and more
- Aug 15, 20132 phase 2 studies in Colorectal NeoplasmsPfizer · NCT01925274, NCT01937715
- May 13, 2014Phase 1 study in HealthyPfizer · NCT02142920 · 6 enrolled · United Kingdom
- Feb 10, 2016Celcuity's first study: phase 1 study in Breast NeoplasmsNew to CelcuityCelcuity · NCT02684032 · 141 enrolled · United States
- Aug 12, 2022Phase 3 study in Breast NeoplasmsCelcuity · NCT05501886 · 701 enrolled · United States, Argentina, Australia and more
- Dec 13, 2023Phase 2 study in Genital Diseases, MaleCelcuity · NCT06190899 · 54 planned · United States, France, Spain and more
- Dec 24, 2024Phase 3 study in Breast NeoplasmsCelcuity · NCT06757634 · 1,180 planned · United States, Argentina, Australia and more
Ahead
- Jan 2028Primary completion: phase 2 study in Genital Diseases, MaleCelcuity · NCT06190899
- Mar 31, 2029Primary completion: phase 3 study in Breast NeoplasmsCelcuity · NCT06757634
TargetBeta
“An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, ”NCIt, by rule
“Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06757634Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Celcuity | Mar 31, 2029 | 1,180 |
| NCT06190899Genital Diseases, Male · United States, France, Spain and more | 2 | Recruiting | Celcuity | Jan 2028 | 54 |
| NCT05501886Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Celcuity | Jun 30, 2026 | 701 |
| NCT02684032Breast Neoplasms · United States | 1 | Completed | Celcuity | Jan 19, 2022 | 141 |
| NCT02142920Healthy · United Kingdom | 1 | Completed | Pfizer | Aug 2014 | 6 |
| NCT01937715Colorectal Neoplasms · United States, Canada, Spain | 2 | Terminated | Pfizer | Aug 2015 | 18 |
| NCT01925274Colorectal Neoplasms · United States, Japan, Korea, Republic of and more | 2 | Terminated | Pfizer | Apr 6, 2016 | 19 |
| NCT01420081Endometrial Neoplasms · United States, Australia, Canada and more | 2 | Terminated | Pfizer | Apr 30, 2014 | 67 |
| NCT00940498Neoplasms · United States, Spain, United Kingdom | 1 | Completed | Pfizer | Aug 2011 | 78 |
How it is read
Names in the registry
- “PF-05212384”, 6 entries
- “Gedatolisib”, 3 entries
- “Arm A: Gedatolisib + Palbociclib + Fulvestrant”, 1 entry
- “Arm C: Gedatolisib + Palbociclib + Letrozole”, 1 entry
- “PF-05212384 (also known as PKI-587)”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Prostatic Neoplasms, Castration-Resistant, 1 study
- Endometrial Neoplasms, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.